29PD - Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition
| Date | 17 December 2016 |
| Event | ESMO Asia 2016 Congress |
| Session | Basic science and translational research |
| Topics | Gastric Cancer Translational Research |
| Presenter | Jing Li |
| Citation | Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574 |
| Authors |
J. Li, J. Tong
|
Abstract
Background
Recent studies indicated that some glycolytic enzymes are complicated, multifaceted proteins rather than simple components of the glycolytic pathway. FBP1 plays a vital role in glucose metabolism, but its role in gastric cancer tumorigenesis and metastasis has not been fully understood.
Methods
The prognostic value of FBP1 was first studied in The Cancer Genome Atlas (TCGA) database and validated in an in-house database. The effect of FBP1 on cell proliferation and metastasis was examined in vitro. Nonparametric test and Log-rank test were used to evaluate the clinical significance of FBP1 expression.
Results
In the TCGA cohort, FBP1 mRNA level were shown to be predictive of overall survival in gastric cancer (P = 0.029). In the validation cohort, FBP1 expression wasinversely correlated with advanced N stage (P = 0.021) and lymphovascular invasion (P = 0.011). Survival analysis demonstrated that FBP1 was an independent predictor for both overall survival (P = 0.004) and disease free survival (P
Conclusions
In conclusion, downregulation of FBP1 promotes gastric cancer metastasis by facilitating EMT and acts as a potential prognostic factor and therapeutic target in gastric cancer.
Clinical trial indentification
Legal entity responsible for the study
JIng Li
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.